氟达拉滨治疗慢性淋巴细胞白血病的疗效及其对生存率的影响

Effect of fludarabine on treatment of patients with chronic lymphocytic leukemia and its influence on survival rate

  • 摘要: 目的:探讨氟达拉滨治疗慢性淋巴细胞白血病(CLL)的疗效及其对生存率的影响。方法选取本院血液科收治的老年 CLL 患者32例,均给予氟达拉滨治疗,并细分为0~Ⅱ期和Ⅲ~Ⅳ期组。另选取30例体检的健康老年患者作为对照组。比较各组患者外周血淋巴细胞亚群数量,分析完全缓解率与临床各相关因素的关系及评价化疗后患者3年的生存率。结果对照组的 CD4+ T 细胞数显著高于Ⅲ~Ⅳ期组患者(P <0.01);对照组的 CD4+/CD8+值显著高于0~Ⅱ期和Ⅲ~Ⅳ期组患者(P <0.05)。氟达拉滨治疗后,CLL 患者的 CD4+T 和 CD4+/CD8+比值显著升高(P <0.05);治疗后完全缓解率与患者的年龄、分期和疗程密切相关;患者的3年存活率为65.6%。结论氟达拉滨能显著改善患者的免疫状态,提高患者的完全缓解率和生存率。

     

    Abstract: Objective To explore the effect of fludarabine on treatment of patients with chronic lymphocytic leukemia (CLL)and its influence on survival rate.Methods 32 elderly pa-tients with CLL were treated with fludarabine,and they were also divided into stage 0~Ⅱ (n =17)group and stage Ⅲ~Ⅳ (n =15)group according to clinical stage of disease.30 elderly pa-tients with medical examination were designed as control group.Number of peripheral blood lym-phocyte were compared between 3 groups,and the relationship between complete remission rate and the clinical related factors as well as survival rate within post-treatment 3 years in CLL pa-tients were observed.Results The number of CD4+ T cells in the control group was significantly higher than that in the stage Ⅲ~Ⅳ group (P <0.01).The number of CD4+ /CD8+ in the control group was significantly higher than that in the treatment group(P <0.05).There was a close rela-tionship between the complete remission rate of fludarabine treatment and the patient’s age,stag-ing and course of treatment.The survival rate within post-treatment 3 years was 65.6%.Con-clusion Fludarabine can significantly improve the patients′immune status and increase the com-plete remission rate and survival rate.

     

/

返回文章
返回